Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement: Monoclonal Antibodies Against SARS-CoV-2
August 26, 2021 – The Sickle Cell Disease Association of America Medical and Research Advisory Committee has released a statement with updated COVID-19 guidance.
MARAC recommends that people with sickle cell disease should have access to monoclonal antibody (mAbs) treatment according to established guidelines, to prevent mild COVID from progressing to severe disease.
Read the full recommendations for providers, policy makers and patients.
+myBinderRelated Content
-
Sickle Cell Treatment ‘Life-Changing’ for Brockton BrothersEmmanuel “Manny” Johnson, 21, of Bro...
-
UH Researcher Reports the Way Sickle Cells Form May Be Key to Stopping ThemUniversity of Houston associate professo...
-
ASH offers early look at updated SCD guidelines: Experts formulated >50 recommendations on sickle cell diseaseThe American Society of Hemato...
-
Diana Wells RN, MSW, MPHDiana Wells serves as a clinical social ...
-
Arrey Echi Agor NdakawArrey Echi Agor Ndakaw is the Interim Vi...
-
A Validated Measure of Adherence to Antibiotic Prophylaxis in Children With Sickle Cell DiseaseAntibiotic prophylaxis is a mainstay in ...
-
Metropolitan Seattle Sickle Cell TaskforceThe Metropolitan Seattle Sickle Cell Tas...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.